Canada markets open in 2 hours 1 minute

Theralase Technologies Inc. (TLT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.2500-0.0050 (-1.96%)
At close: 3:59PM EDT
Full screen
Previous Close0.2550
Bid0.2450 x 0
Ask0.2500 x 0
Day's Range0.2450 - 0.2600
52 Week Range0.1200 - 0.3200
Avg. Volume381,413
Market Cap51.069M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateApr. 27, 2021 - May 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreet

    Stocks in play: Theralase® Technologies Inc.

    Has executed a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health ...


    Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine

    TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc.Under the terms of the agreement, Theralase® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase®'s patented PDC and then light activating it with Theralase®'s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine.


    Theralase Launches Anti-Cancer Therapy Research Centre

    TORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today the launch of the Theralase® Anti-Cancer Therapy ("ACT") research centre located within the Li Ka Shing Knowledge Institute of St.